Efficacy and Toxicity of Bevacizumab on Combination with
Chemotherapy in Different Lines of Treatment for Metastatic
Colorectal Carcinoma

J 2014

Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma

KISS, Igor, Zbyněk BORTLÍČEK, Bohuslav MELICHAR, Alexander POPRACH, Jana HALÁMKOVÁ et. al.

Základní údaje

Originální název

Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma

Autoři

KISS, Igor (203 Česká republika), Zbyněk BORTLÍČEK (203 Česká republika, garant, domácí), Bohuslav MELICHAR (203 Česká republika), Alexander POPRACH (203 Česká republika), Jana HALÁMKOVÁ (203 Česká republika), Rostislav VYZULA (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí) a Tomas BUCHLER (203 Česká republika)

Vydání

Anticancer Research, Athens, International Institute of Anticancer Research, 2014, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.826

Kód RIV

RIV/00216224:14110/14:00078690

Organizační jednotka

Lékařská fakulta

UT WoS

000331497200056

Klíčová slova anglicky

Colorectal cancer; metastasis; bevacizumab; chemotherapy; survival

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 10. 2017 15:24, Soňa Böhmová

Anotace

V originále

The aim of the present study was to describe treatment outcomes for bevacizumab in combination with chemotherapy based on data from the Czech registry of targeted therapies for metastatic colorectal cancer (mCRC). Patients and Methods: In total, 4,487 patients with mCRC who received bevacizumab combined with chemotherapy in first line (n=3,990, 88.9%), second line (n=386, 8.6%), or third/higher line (n=111, 25%) had evaluable data and were included in the present retrospective analysis. Results: The median progression-free survival (PFS) was 11.3 months (95% conficence interval [CI]=11.0-11.7 months), 9.5 months (95% CI=8.2-10.9 months), and 7.3 months (95% CI=5.9-8.7 months; p<0.001), and the median overall survival from the start of bevacizumab-containing therapy was 28.4 months (95% CI=27.1-29.8 months), 25.9 months (95% CI=19.4-32.4 months), and 15.0 months (95% CI=10.7-19.3 months; p<0.001), respectively. Conclusion: The data describe efficacy of bevacizumab with chemotherapy for different treatment lines in a large patient cohort.

Citovat

KISS, Igor, Zbyněk BORTLÍČEK, Bohuslav MELICHAR, Alexander POPRACH, Jana HALÁMKOVÁ, Rostislav VYZULA, Ladislav DUŠEK a Tomas BUCHLER. Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma. Anticancer Research. Athens: International Institute of Anticancer Research, 2014, roč. 34, č. 2, s. 949-954. ISSN 0250-7005.

@article{1218642,
   author = {Kiss, Igor and Bortlíček, Zbyněk and Melichar, Bohuslav and Poprach, Alexander and Halámková, Jana and Vyzula, Rostislav and Dušek, Ladislav and Buchler, Tomas},
   article_location = {Athens},
   article_number = {2},
   keywords = {Colorectal cancer; metastasis; bevacizumab; chemotherapy; survival},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma},
   volume = {34},
   year = {2014}
}

TY  - JOUR
ID  - 1218642
AU  - Kiss, Igor - Bortlíček, Zbyněk - Melichar, Bohuslav - Poprach, Alexander - Halámková, Jana - Vyzula, Rostislav - Dušek, Ladislav - Buchler, Tomas
PY  - 2014
TI  - Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma
JF  - Anticancer Research
VL  - 34
IS  - 2
SP  - 949-954
EP  - 949-954
PB  - International Institute of Anticancer Research
SN  - 02507005
KW  - Colorectal cancer
KW  - metastasis
KW  - bevacizumab
KW  - chemotherapy
KW  - survival
N2  - The aim of the present study was to describe treatment outcomes for bevacizumab in combination with chemotherapy based on data from the Czech registry of targeted therapies for metastatic colorectal cancer (mCRC). Patients and Methods: In total, 4,487 patients with mCRC who received bevacizumab combined with chemotherapy in first line (n=3,990, 88.9%), second line (n=386, 8.6%), or third/higher line (n=111, 25%) had evaluable data and were included in the present retrospective analysis. Results: The median progression-free survival (PFS) was 11.3 months (95% conficence interval [CI]=11.0-11.7 months), 9.5 months (95% CI=8.2-10.9 months), and 7.3 months (95% CI=5.9-8.7 months; p<0.001), and the median overall survival from the start of bevacizumab-containing therapy was 28.4 months (95% CI=27.1-29.8 months), 25.9 months (95% CI=19.4-32.4 months), and 15.0 months (95% CI=10.7-19.3 months; p<0.001), respectively. Conclusion: The data describe efficacy of bevacizumab with chemotherapy for different treatment lines in a large patient cohort.
ER  -

KISS, Igor, Zbyněk BORTLÍČEK, Bohuslav MELICHAR, Alexander POPRACH, Jana HALÁMKOVÁ, Rostislav VYZULA, Ladislav DUŠEK a Tomas BUCHLER. Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2014, roč.~34, č.~2, s.~949-954. ISSN~0250-7005.

Podrobný výpis o publikaci